Posted on July 27, 20227/27/22
EVERSANA’s Continued Commitment to Rare Disease
Posted on July 14, 20217/14/21
Navigating the Transition to Post-Approval Pharmacovigilance With EVERSANA and ArisGlobal
Posted on January 19, 20211/19/21
The 10-Year Test: Is It Possible to Plan Launch During Clinical Development?
Posted on December 16, 202012/16/20
Insights From Dreamforce 2020 Panel: End-To-End Patient Engagement
Posted on November 30, 202011/30/20
Case Study: Early-Stage Asset Valuation
Posted on November 24, 202011/24/20
How Artificial Intelligence Is Transforming Pharma
Posted on October 28, 202010/28/20
NORD 2020 Insights: Entering a New Era
Posted on September 8, 20209/8/20
Doing the Right Things Right: A Perspective on Rare Disease Drug Development
Posted on August 31, 20208/31/20
Looking To Launch Or Commercialise In The US?
Posted on April 15, 20204/15/20